Arcellx (ACLX) Gains from Investment Securities (2021 - 2025)
Arcellx (ACLX) recorded quarterly Gains from Investment Securities of $546938.0 in Q3 2025, down 47.66% quarter-over-quarter from $1.0 million in Q2 2025, and up 36.39% on a YoY basis from $401000.0 in Q3 2024.
Arcellx (ACLX) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Arcellx's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $546938.0 for Q3 2025.
- In Q3 2025, Gains from Investment Securities rose 36.39% year-over-year to $546938.0; the TTM figure through Dec 2025 stood at -$193000.0 (changed N/A YoY), while the FY2025 annual figure was $6.8 million, down 6.45% from the prior year.
- Gains from Investment Securities was $546938.0 for Q3 2025 at Arcellx, down from $1.0 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $15.4 million in Q4 2023 to a low of -$9.3 million in Q4 2022.
- Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $703329.0 in 2022.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities jumped 1135.48% in 2022, then slumped 200.32% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at -$333000.0 in 2021, then tumbled by 2692.19% to -$9.3 million in 2022, then surged by 265.43% to $15.4 million in 2023, then sank by 109.54% to -$1.5 million in 2024, then surged by 137.28% to $546938.0 in 2025.
- The last three Gains from Investment Securities figures came in at $546938.0 (Q3 2025), $1.0 million (Q2 2025), and $229000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 546,938.00 |
| Sep 30, 2025 | 546,938.00 |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | -1.47 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | 401,000.00 |
| Sep 30, 2024 | 401,000.00 |
| Jun 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.52 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Mar 31, 2024 | 7.59 Mn |
| Dec 31, 2023 | 15.38 Mn |
| Dec 31, 2023 | 15.38 Mn |
| Jun 30, 2023 | 6.50 Mn |
| Jun 30, 2023 | 6.50 Mn |
| Mar 31, 2023 | 745,660.00 |
| Mar 31, 2023 | 745,660.00 |